Effects of cyclosporin A on the development of immune-mediated interstitial nephritis  by Shih, Winston et al.
Kidney International, Vol. 33 (1988), pp. 1/13—1/18
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Effects of cyclosporin A on the development of immune-mediated
interstitial nephritis. We examined the effect of daily cyclosporin A
administration on the development and extent of tubulointerstitial
nephritis produced in rats immunized with tubular basement mem-
branes in adjuvant. Six mg/kg/day of cyclosporin A, given from the time
of immunization, completely blocked the development of interstitial
lesions and renal insufficiency. The administration of cyclosporin A
after the development of interstitial nephritis also arrested the progres-
sion of the histological lesions. Both T cell-mediated and humoral
immunity were markedly reduced by the administration of cyclosporin
A, as evidenced by the near absence of delayed-type hypersensitivity
responses and by the reduced production of anti-tubular basement
membrane antibodies. Cell admixture experiments indicated that im-
pairment of the delayed-type hypersensitivity response to tubular
antigen was probably not the result of active suppression, and sug-
gested that the protective effect of cyclosporin A might be secondary to
its direct inhibitory action on the activation of nephritogenic T and B
cells. Finally, the treatment of control rats with cyclosporin A, in the
doses used, did not produce any detectable kidney damage nor did it
impair renal function. We conclude that cyclosporin A can be an
effective prophylactic and therapeutic agent in autoimmune interstitial
nephritis in rats.
Brown Norway rats immunized with renal tubular antigen in
adjuvant develop severe interstitial nephritis. The expression of
disease is characterized by the appearance of anti-tubular
basement membrane antibodies (aTBM-Ab) followed by an
intense mononuclear cell infiltrate composed of T lymphocytes,
macrophages and Ig cells 11—31. Because this autoimmune
process is a reproducible model of experimental interstitial
nephritis, and because of the ability of cyclosporin A (CSA) to
inhibit T cell activation in vitro and act as an immunomodulat-
ing agent [4], we chose to study the effect of CSA on the
generation and progression of primary interstitial nephritis.
While CSA has been implicated as a cause of dose-dependent
interstitial injury [5, 6, 71, it also is effective in the prevention of
organ transplant rejection [81 and in the treatment of a number
of experimental autoimmune diseases, including allergic enceph-
alomyelitis, glomerulonephritis, uveitis and spontaneous diabe-
tes mellitus [9—13]. The experimental and clinical efficacy of this
drug, however, has not been evaluated in the setting of immune-
mediated interstitial renal disease.
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Methods
Animals
Brown Norway rats weighing 100 to 120 grams were obtained
from the Charles River Breeding Laboratories (Wilmington,
Massachusetts, USA), and maintained by the Department of
Laboratory and Animal Medicine at the University of Pennsyl-
vania.
Immunization
Rabbit renal tubular basement membrane antigen (RTA) was
prepared as previously described [14]. Groups of rats were
immunized with 2 mg of RTA in complete Freund's adjuvant
(CFA) in hind footpads and four quadrants. Control animals
received CFA alone.
Cyclosporine administration
Cyclosporin A (CSA; Sandoz Ltd., East Hannover, New
Jersey, USA) 50 mg/mI in olive oil was diluted in normal saline
to a concentration of 4 mg/mI. The drug was administered
subcutaneously at 6 mg/kg/day. Two drug intervals were used
for analysis. In some groups CSA was administered from days
Ito 27 after immunization (Groups A—F); in other cohorts it was
given from days 15 to 36 (Groups G—I). Animals were sacrificed
on days 15, 27, or 36. Control animals received either equal
volumes of normal saline (PSS), olive oil, or did not receive any
treatment.
Assessment of renal disease
Kidney tissue was prepared for immunofluorescent and light
microscopy by standard methods [15]. Direct immunofluores-
cence of tubular staining by aTBM-Ab was graded by a blind
observer on a scale of 0 to 4 and expressed as mean SEM for
each group. Kidneys fixed in 10% formalin were stained with
hematoxylin and eosin. Multiple longitudinal sections were
examined in a group-blind fashion and graded (mean 5EM)
according to the extent of cortical involvement on a scale of 0 to
4(0 = normal; 0.5 = small focal areas of cellular infiltration and
tubular damage; 1 = involvement of less than 10% of the cortex;
2 = involvement up to 25% of the cortex; 3 = involvement up
to 50 to 75% of the cortex; and 4 = extensive damage involving
more than 75% of the cortex). The presence of aTBM-Ab in
serum was determined by solid-phase radioimmunoassay against
SRTA [I]. Serum creatinines were measured using the modified
methods of Jaffe [16].
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Table 1. Effects of early cyclosporin A administration on the course of interstitial nephritis
Group Immunizationa Treatmentb NC Bound aTBMAbd Histologic severitye Serum creatinine
A RTA/CFA — 6 3.7 0.2 2.8 0.4 1.29 0.37
B RTA/CFA PSS 8 2.5 0.2 2.0 0,5 1.19 0.26
C RTA/CFA Olive oil 4 — 3.1 0.6 —
D RTA/CFA CSA 6 0.0 0.0 0.1 0.1 0.72 0,02g
E CFA — 6 0.0 0.0 0.0 0.0 0.70 0.01
F CFA CSA 4 0.0 0.0 0.0 0.0 0.72 0.02
a All animals were sacrificed 27 days after immunization.
h CSA was diluted in PSS and given at dose of 6 mg/kg/day in approximately 0.2 ml of volume/rat from days Ito 27 after immunization. PSS was
given at 0.2 mI/rat/day from days I to 27 after immunization.
C Number of animals/group.
d Intensity of direct immunofluorescence expressed as mean SEM.
Graded histologic sections reported as the mean SEM.
Creatinines reported as mean mg% SEM.
P < 0.01 compared to Group A or B.
Induction and elicitation of delayed-type hypersensitivity
(DTH) responses
Groups of rats were challenged in the footpads with 50 g of
soluble antigen (SRTA or PPD) in 50 d of phosphate-buffered
saline (PBS) [14]. Twenty-four hours later, just prior to sacri-
fice, footpad swelling as an index of DTH was measured with a
spring-loaded engineer's micrometer (Schlesinger's For Tools,
Ltd., Brooklyn, New York, USA). The magnitude of swelling
was expressed as the mean increment between the footpad prior
to and following antigen challenge in inches >< lO SEM [2,
14]. Native rats were also challenged with PPD and SRTA, and
swelling was measured as above. All measurements were
cage-blind.
Adoptive transfer of DTH responses
Spleen cells were prepared from various immune donor
animals 27 days after immunization. Cells were suspended in
RPMI 1640 supplemented with 5% fetal calf serum and antibi-
otics. Cells were washed once, passed through a nylon mesh to
remove debris and resuspended in PBS. The spleen cells of
various immune donor animals were combined in different
ratios, and native, syngeneic recipient rats received an intra-
cardiac injection of admixed cells in 0,2 ml of volume. Soon
after adoptive transfer each recipient was challenged with
antigen [14], and DTH responses were measured twenty-four
hours later.
Statistical analysis
Differences between experimental groups were determined
either by Student's t-test or Wilcoxon rank sum.
Results
Effects of early cyclosporin administration on the
development of disease
Five groups of animals were immunized on day I and
sacrificed and studied on day 27 (Table I, Fig. I). Groups A, B,
and C were immunized with RTA in CFA and received either no
treatment, normal saline, or olive oil, respectively; they did not
receive CSA and served as the positive disease controls.
Groups E and F were immunized with CFA to provide non-
disease controls. Animals receiving daily CSA beginning on the
Table 2. Effect of early cyclosporin A administration of delayed-type
hypersensitivity
Group DTH responsea
Immunization Treatmentb SRTA PPD
—
RTA/CFA GSA 2.8 Ø9C 4.5 1.6c
CFA GSA 3.0 l.2C 2.5 l.0'
CFA
—
— 2.5 0.9C 36.3 1.4
— 3.0 1.3 3.8 0.7
a DTH responses were read on day 27, 24 hours after antigen
challenge, and were calculated as the mean increment in inches X l0
SEM. Each group consisted of 4 animals.
b CSA was diluted in PSS and given at dose of 6 mg/kg/day from day I
to 27 after immunization.
C P < 0.001 compared to immunized controls.
day of immunization with RTA in CFA (Group D) neither
developed histological lesions nor kidney-bound aTBM-Ab
when compared to positive controls. The serum creatinine
values from Group D were also similar to the negative controls
(Groups E and F). Serum aTBM-Ab titers (Fig. 2A) against
SRTA in Group D were negligible compared with positive
disease controls (Groups A and B), and were indistinguishable
from rats immunized with CFA alone (Groups E and F). The
administration of GSA to rats immunized with CFA alone
(Group F) did not result in interstitial lesions or renal insuffi-
ciency.
We were also interested in determining the impact of CSA on
the effector T cell-mediated immune response to tubular anti-
gen. We have previously demonstrated that a delayed-type
hypersensitivity (DTH) response to tubular antigen is a T
cell-dependent and antigen-specific measure of nephritogenic
potential [2]. Results in Table 2 demonstrate that rats treated
from days I to 27 with 6 mg/kg/day of GSA developed a
non-specific and severe impairment of DTH, as the responses to
both SRTA and PPD were totally abolished. Adoptive transfer
experiments in Table 3 indicate this unresponsiveness to SRTA
was probably not the result of active suppression. Administra-
tion of several doses of immune spleen cells from CSA-treated
animals with a constant number of non-CSA-treated effector
cells failed to show any suppression of the DTH response to
tubular antigen in native recipients.
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Fig. 1. Effects of cyclosporin A on the
development and extent o.f interstitial nephritis.
A. Renal Cortex from a rat receiving RTA/CFA
on day I who was sacrificed on day 36 (Group
H). There are extensive interstitial infiltrates
present. B. Renal cortex from a rat receiving
RTA/CFA and CSA (6 mg/kg) from day I who
was sacrificed on day 27 (Group D). There is
normal preserved interstitial architecture. C.
Renal cortex from a rat receiving RTA/CFA on
day I and CSA beginning on day 15 (6 mg/kg)
who was sacrificed on day 36 (Group I). There
are only scattered interstitial infiltrates
(hematoxylin and eosin; 160 x original
magnification).
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Fig. 2. Serum aTBM-Ab titers following immunization. Serial dilutions
of immune serum were titered against solubilized tubular antigen by
radioimmunoassay [31. A. uTBM-Ab titers from rats reported in Table
1: (—•—) RTA/CFA; (—A—) RTA/CFA + PSS; (—•—) RTA/CFA +
6 mg/kg/day cyclosporin A (day 1 to 27); and (N) CFA. B. sTBM-Ab
titers from rats reported in Table 4: (—•—) RTAICFA (day 36): (—A—)
RTA/CFA (day 15); and (—•—) RTA/CFA + 6 mg/kg/day cyclosporin
A (day 15 to 35).
ffects of late cyclosporin A on the course of interstitial
nephritis
Three additional groups were studied to evaluate the effects
of CSA on established interstitial disease (Table 4, Fig. 1).
Non-drug treated rats immunized with RTA in CFA were
sacrificed on day 15 and 36 (Groups G and H, respectively).
Another group received 6 mg/kg/day of cyclosporin from days
15 to 36 (Group I). By 15 days after immunization with RTA in
CFA, the time-control rats (Group G) had already developed
substantial interstitial lesions. The degree of interstitial damage
progressed by day 36 in untreated rats and was associated with
an elevated serum creatinine. The group receiving CSA begin-
ning on day 15 (Group I) did not progress, and had a slightly
reduced histologic score, although not statistically significant,
when compared to rats sacrificed on day 15 (0.4 vs. 1.4). CSA
treatment also had a protective effect on serum creatinine. The
amount of kidney-bound sTBM-Ab was significantly decreased
in CSA-treated rats compared to the untreated animals. CSA
treatment beginning on day 15 also markedly decreased, but did
not completely abolish serum aTBM-Ab titers against SRTA
(Fig. 2B). Furthermore, in Table 5, the administration of CSA
after the development of interstitial nephritis markedly dimin-
ished the DTH response to SRTA and PPD compared with
untreated animals on day 36.
Discussion
Previous studies from our laboratory have suggested that low
protein diet [17] and cyclophosphamide [141 were effective
therapeutic modalities in an animal model of immune-mediated
interstitial nephritis. The present study indicates that CSA at 6
mg/kg/day can also completely prevent the development of
primary interstitial renal lesions in rats when administered from
the time of immunization. Both T cell-mediated and humoral
Donor cellsa N" DTH response to SRTAC
30 x 106 RTA/CFA + 150 x 106 3 24.3 1.2
RTA/CFA/CSA
30 x 10" RTA/CFA + 90 x 106 3 23.3 2.4
RTA/CFA/CSA
30 x 106 RTA/CFA + 30 x 106 7 25.7 2.0
RTA/CFA/CSA
30 x 106 RTA/CFA + 30 x 106 4 21.8 1.2
RTA/CFA
30 x 106 RTA/CFA + 30 x 106 3 25.0 1.6
CFA
30 x 10" CFA + 30 >( 106 3 3.3 0.9
CFA
a Each naive recipient received the indicated cells in 0.2 ml of PBS
via intracardiac injection. The donor cells were splenocytes harvested
27 days after immunization and were admixed immediately prior to
injection.
b Number of animals/group.
DTH responses were calculated as the mean increment in inches x
iO SEM and were measured 24 hours after antigen challenge.
immunity were abrogated by the early administration of CSA as
evidenced by the absence of interstitial damage, DTH response,
and aTBM-Ab. The inability to suppress the DTH response to
tubular antigen in naive rats receiving an admixture of immune
cells from CSA and non-CSA treated donors indicates that the
absence of a T cell-mediated response was not due to active
suppression. From these current experiments, the protective
effect of CSA appears to be secondary to its direct inhibitory
action on the activation of nephritogenic T and B cell mecha-
nisms of injury.
The administration of CSA during the development of inter-
stitial nephritis arrested the progression of the histological
lesion, aTBM-Ab production, and renal insufficiency. This
finding suggests that the activity of existing nephritogenic cells
at day 15 was held in check by the administration of CSA.
Cell-mediated immunity as judged by the DTH response to
SRTA or PPD was also markedly inhibited by delayed CSA
treatment.
The ability of CSA to inhibit T cell activation in vitro has led
to the expectation that it can function as an immunotherapeutic
agent in certain autoimmune diseases in which cellular immu-
nity plays a prominent role [4, 9—12, 18]. CSA appears to inhibit
the secretion of IL-2 by T-helper/inducer cells and leads to
blunting of the activation of effector T cell populations. The
development of cell-mediated autoimmune lesions has been
inhibited by CSA administration in several animal models
including allergic encephalornyelitis, glomerulonephritis, arthri-
tis, uveitis and spontaneous diabetes mellitus [9—13, 19]. Cellu-
lar immunity as measured by DTH response is markedly
diminished when CSA is administered daily from the time of
immunization [19, 201. DTH is also inhibited when CSA is given
only immediately before and after skin testing, probably due to
a decrease in the lymphokine production needed for T cell
proliferation and recruitment [20]. Some investigators have
reported that delayed administration of CSA can lead to an
exacerbation of autoimmune disease and DTH [19], while
others have shown inhibition of disease when CSA is given
during the effector phase [13]. When CSA is given at the time of
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Table 4. Effect of late cyclosporin A administration on the course of interstitial nephritis
Group Immunization CSA N' Sacrifice day Bound aTBM-Ab Histological severity Serum creatinine
G RTA/CFA — 8 15 1.9 0.8 1.4 0.7 0.84 0.1
H RTA/CFA — 5 36 3.6 0.5 3.4 0.2 3.21 0.15
I RTA/CFA + 6 36 1.3 0.2c 0.4 0.3c 0.79 QØ3C
a CSA was given daily at 6 mg/kg/day from day 15 to 36 after immunization.
b Numberof animals/group.
P < 0.01 compared to Group H.
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DTH responses were calculated as the mean increment in inches x
l0- SEM, 24 hours after antigen challenge, 36 days after immuniza-
tion.b CSA was diluted in PSS and given at dose of 6 mg/kg/day in
approximately 0.2 ml of volume from day IS to 36 after immunization.
P < 0.01 compared to immunized controls.
lated to be mediated by sparing of suppressor T cells with a
resultant change in immune balance [211. However, in delayed
CSA administration during active cell-mediated immune re-
sponses, the potentiation of disease seen with some models has
been postulated to be due to selective down-regulation of
suppressor cells more than effector cells [19]; this has yet to be
proven experimentally. The studies in this paper demonstrate a
marked inhibition of the nephritogenic T cell and DTH re-
sponses even in the setting of delayed CSA therapy. Further-
more, we were unable to demonstrate that this improvement of
disease was mediated by active suppression.
The role of CSA in inhibiting humoral immunity is less clear.
The results of in vitro studies suggest that B cell activation is
CSA sensitive in its early stages, and resistant in later phases
[41. In studies of MRL-lpr/lpr lupus-susceptible mice treated
with CSA, there was a diminution in lymphadenopathy, glomer-
ulonephritis and arthritis, prolonged survival, and decreased
numbers of L3T4 cells. However, there was no reduction in
anti-DNA antibodies, immune complexes or circulating immu-
noglobulin [II]. Similar findings have been reported in a small
series of patients with steroid-resistant systemic lupus eryther-
matosus treated with CSA [18]. Yet, in studies of rodent
experimental arthritis, CSA given from the time of immuniza-
tion or given during the early effector phase of disease produced
a marked suppression of humoral immunity, whereas CSA
given later in the effector phase did not change the antibody
titers [191. Experimental work in the mouse suggests that most
B cells are resistant to CSA except for a subset which are
dependent upon T cells for activation [22]. Thus, previous work
suggests that T-dependent, unprimed B cells responses are
sensitive to CSA whereas primed antibody responses are rela-
tively resistant. The studies presented here document an im-
pairment of humoral immunity in experimental interstitial ne-
phritis both when CSA is given at the time of immunization and
during the effector phase. This appears to be the first observa-
tion of CSA interrupting an established B cell response. It is
important to note that the inhibition of a aTBM-Ab in these
experiments cannot by itself explain the lack of interstitial
nephritis, since passively administered cffBM-Ab in BN rats
does not lead to the development of interstitial nephritis (data
not shown).
The possibility of long-term toxicity induced by CSA therapy
in BN rats was not addressed in the present experiments. These
studies also did not look at extra-renal toxicity, and did not
investigate what might happen to successfully treated rats after
the drug is stopped. There has been a reported increase in
autoimmunity in rats receiving interrupted courses of CSA [23].
Further studies will be needed to address whether the effect of
CSA on interstitial nephritis is specific to strain, species or
regimen.
One of the adverse side effects of CSA therapy in humans is
the development of chronic nephrotoxicity characterized by
patchy interstitial fibrosis, focal and segmental glomeruloscle-
rosis, hyalinosis of small arteries and arterioles and progressive
decline in renal function [5]. There are no adequate experimen-
tal models for chronic renal damage by CSA, and rats in
particular are relatively resistant to this lesion. Only one
pharmacokinetic study of CSA in rats demonstrated dose-
dependent nephrotoxicity [241, but at doses which far exceed
human regimens and which can cause rodent neurotoxicity
before any renal changes are noted [251, In the present study,
the dose of CSA employed was comparable to therapeutic
regimens in humans and was effective in interrupting the
nephritogenic immune response. Although no nephrotoxicity
was seen, the resistance of rats to CSA renal toxicity implies
that some caution must be used in extrapolating these results to
human interstitial nephritis.
In conclusion, we have demonstrated that CSA is an effective
prophylactic and therapeutic agent for T and B cell nephrito-
genic effector mechanisms in autoimmune interstitial nephritis.
This effect can be achieved with doses of CSA comparable to
human regimens. The data suggest two important observations:
First, the beneficial effect of CSA is not due to active suppres-
sion. Second, CSA can interrupt an established B cell response
in this model. The precise mechanism for the ability of CSA to
directly interfere in effector T and B cell mechanisms of injury
will require further study.
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